

17 February 2022

ASX Announcement

## Nasodine US Patent Granted for COVID-19

---

**Firebrick Pharma Limited** (ASX:FRE) (**Company** or **Firebrick**) announced today that the Company's patent application covering the use of Nasodine® Nasal Spray (Nasodine) in COVID-19 had been granted in the US.

The US patent dated 15 February 2022, is titled: *"Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes."*

A notice of allowance in the US for this patent was disclosed in the Company's Prospectus (section 5 and page 7). A copy of the granted, published patent (US Patent 11,246,887) will be available on the Company's website.

"This patent covers the use of any povidone-iodine formulation in the nose for reducing the viral load of SARS-CoV-2, the virus that causes COVID-19," said Firebrick Executive Chairman, Dr Peter Molloy. "Any person or company promoting or selling a povidone-iodine nasal spray in the US for this or a related purpose is most likely infringing our patent."

The patent has also been filed in Europe, Japan and other countries, as described in the Prospectus (section 5) and granted as an Innovation Patent in Australia.

The Company noted that Nasodine had been developed primarily as a treatment for the common cold, which is covered by a separate family of granted patents. The Company also emphasised that Nasodine is not yet approved for sale in Australia or elsewhere and any use in COVID-19 would be strictly subject to additional regulatory approvals for that indication.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

**About Firebrick (ASX:FRE)**

Firebrick is a pharmaceutical company founded in 2012 by Peter Molloy and Stephen Goodall to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold. The Company also owns a patent family that covers the use of intranasal povidone-iodine for the prevention of pandemic viral diseases, including COVID-19.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

**Investor enquiries:**

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)